About CDT 2020 Program Registration Venue

Cancer Diagnosis

Can Technology Achieve Early Diagnosis?


It is generally recogonised that early diagnosis significantly improves cancer survival rates. The role of technology in achieving that desirable objective is more contentious. In the United States $billions are being invested in blood biopsy development. The United Kingdom, which has among the lowest survival rates in Europe, is sceptical that technlogy will do little more than monitor pre-diagnosed cancers., The Cancer Diagnostic Technology Summit will address this problem by inviting leading developers of cancer diagnostic technology to make their case to clinicians.

Key Technologies



Blood biopsy

Biomarkers in breath, saliva and urine

Cell separation and DNA sequencing

AI in imaging and data mining

Call for Papers



Contact Sensor100 if you would like to present at CDT20:

Companies with cancer diagnostic technology at any stage of development

Early stage companies developing innovative diagnostic technology

Academic and clinical research teams

Send a brief abstract to cdt20@sensor100.com

Follow the Template Guidelines for inclusion in the Conference Book of Abstracts

Abstract deadline: 21 February 2020

Supported by



Imperial College Network of Excellence in Cancer Technology

Organising Committee

Dr. Michael Brand, Sensor100

Dr. Kalypso Charalambous, Institute of Biomedical Engineering, Imperial College London

Dr. Sylvain Ladame, Department of Bioengineering, Imperial College London